Erythropoietin biosimilar - Curaxys
Latest Information Update: 24 Jun 2015
At a glance
- Originator Curaxys
- Developer Curaxys; University of Cadiz
- Class Antianaemics; Erythropoietins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 24 Jun 2015 Discontinued for Anaemia in Spain (SC)